An extract from the Investor presentation dated 21/02/2024:...

An extract from the Investor presentation dated 21/02/2024:

"Programmed death ligand 1 (PD-L1) expression is an FDA-approved predictive biomarker of the success of PD-1/PD-L1 inhibitor therapy for patients with non-small cell lung cancer. The method used to assess the level of PD-L1 in NSCLC is three different expression levels: high (TPS >50%), low (TPS 1-49%), and negative (TPS <1%) [...]. Generally speaking, the way NSCLC patients are expected to respond to anti-PD-(L)1 therapies is grouped by these three levels of PD-L1 expression: high expressors respond best, low expressors respond sub-optimally, and negative expressors are not expected to respond at all or have negligible responses [...]. For negative expressing patients (TPS <1%), none of these chemo-free IO therapies are approved."